

Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes

Marios K. Georgakis, MD, PhD, Dipender Gill, MD, PhD, Alastair J.S. Webb, DPhil, et al.

Cite as: *Neurology*® 2020;95:e353-e361. doi:10.1212/WNL.0000000000009814

Correspondence

Dr. Dichgans
martin.dichgans@
med.uni-muenchen.de

Study objective

To explore, using Mendelian Randomization, whether the effects of blood pressure (BP) and BP lowering through different antihypertensive drug classes on stroke risk vary by stroke etiology.

What is known and what this paper adds

BP and pharmacotherapy-based BP-lowering regimens are determinants of stroke risk. This study supports a causal role of hypertension in all major stroke subtypes except lobar intracerebral hemorrhage (ICH), and identifies calcium channel blockers (CCB) as promising for prevention of cerebral small vessel disease (SVD).

Participants and setting

Genetic variants associated with BP or the BP lowering effect of antihypertensive medications were assessed in genome-wide association study (GWAS) data from 757,601 patients sourced from a meta-analysis of the International Consortium for BP and the UK Biobank. Genetic associations with stroke were determined using data from the MEGASTROKE multiethnic GWAS that included 67,162 patients with stroke and 454,450 stroke-free controls and from an International Stroke Genetics Consortium (ISGC) meta-analysis that included 1,545 patients with intracerebral hemorrhage (ICH) and 1,481 stroke-free controls.

Design, size, and duration

GWAS data were used to identify single-nucleotide polymorphisms (SNPs) associated with systolic BP (SBP) or diastolic BP (DBP), as well as a list of SBP-associated SNPs in genes that encode targets for common antihypertensive drug classes. Associations with any stroke, ischemic stroke and its subtypes, intracerebral hemorrhage (ICH, deep and lobar), and SVD and white matter hyperintensities (WMH) were examined using 2-sample Mendelian randomization.

Primary outcome measures

The primary outcome was the association of the SNPs noted above with the risk of stroke and stroke subtypes.

Table Selected associations between genetically determined BP and stroke risk

Stroke type	Odds ratio (95% confidence interval) for stroke per	
	10-mm Hg increment in SBP	5-mm Hg increment in DBP
Any stroke	1.39 (1.33–1.44)	1.27 (1.23–1.32)
Ischemic stroke	1.41 (1.35–1.47)	1.28 (1.24–1.33)
ICH	1.41 (1.11–1.79)	1.29 (1.05–1.57)

Main results and the role of chance

Genetic predisposition to higher SBP and DBP was associated with higher risk of any stroke, ischemic stroke, and ICH, as well as all ischemic stroke subtypes (with a higher risk of large artery and small vessel stroke compared to cardioembolic stroke), and deep, but not lobar ICH. Genetically determined BP and genetic proxies for calcium channel blockers, but not beta blockers, were associated with lower risk of any stroke and ischemic stroke. Proxies for CCBs showed particularly strong associations with SVD and WMH.

Bias, confounding, and other reasons for caution

Mendelian randomization analyses include the lifetime effects of genetically determined BP, which may differ from the effect of a clinical antihypertensive intervention. The present study could not provide analyses for angiotensin-converting enzyme inhibitors. Participants were all from European ancestry.

Study funding/potential competing interests

This study was funded by the German Academic Exchange Service, the Onassis Foundation, the Wellcome Trust, the UK Medical Research Council, Public Health England, the Alzheimer's Society, Alzheimer's Research UK, the UK National Institute of Health Research, the European Union, Deutsche Forschungsgemeinschaft, the Corona Foundation, the Fondation Leducq, and the e:Med program. The authors report no competing interests. Go to Neurology.org/N for full disclosures.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The corresponding author(s) of the full-length article and the journal editors edited and approved the final version.

Neurology[®]

Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes

Marios K. Georgakis, Dipender Gill, Alastair J.S. Webb, et al.
Neurology 2020;95:e353-e361 Published Online before print July 1, 2020
DOI 10.1212/WNL.0000000000009814

This information is current as of July 1, 2020

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/95/4/e353.full
References	This article cites 52 articles, 10 of which you can access for free at: http://n.neurology.org/content/95/4/e353.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Cerebrovascular disease/Stroke http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke All Genetics http://n.neurology.org/cgi/collection/all_genetics Intracerebral hemorrhage http://n.neurology.org/cgi/collection/intracerebral_hemorrhage
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

